Extended daily dialysis: A new approach to renal replacement for acute renal failure in the intensive care unit

Citation
Va. Kumar et al., Extended daily dialysis: A new approach to renal replacement for acute renal failure in the intensive care unit, AM J KIDNEY, 36(2), 2000, pp. 294-300
Citations number
15
Categorie Soggetti
Urology & Nephrology
Journal title
AMERICAN JOURNAL OF KIDNEY DISEASES
ISSN journal
02726386 → ACNP
Volume
36
Issue
2
Year of publication
2000
Pages
294 - 300
Database
ISI
SICI code
0272-6386(200008)36:2<294:EDDANA>2.0.ZU;2-T
Abstract
Continuous venovenous hemofiltration (CVVH) is an effective form of renal r eplacement therapy for acute renal failure (ARF) that offers greater hemody namic stability and better volume control than conventional hemodialysis in the critically ill, hypotensive patient. However, the application of CVVH in the intensive care unit (ICU) has several disadvantages, including inten sive nursing requirements, continuous anticoagulation, patient immobility, and expense. We describe a new approach to the treatment of ARF in the ICU, which we have termed extended daily dialysis (EDD). In this study, EDD was compared with CVVH in 42 patients: 25 patients were treated with EDD for a total of 367 treatment days, and 17 patients were treated with CVVH for a total of 113 days. Median treatment time per day was 7.5 hours for EDD (ran ge, 6 to 8 hours, 25th to 75th percentile) versus 19.5 hours for CVVH (rang e, 13.4 to 24 hours; P < 0.001). Mean arterial blood pressures (MAPs) did n ot differ significantly for patients treated with EDD when measured predial ysis (median MAP, 70 versus 67 mm Hg for CVVH; P = 0.078), midway through d aily treatment (70 versus 68 mm Hg for CVVH; P = 0.083), or at the end of t reatment (71 versus 69 mm Hg for CVVH; P = 0.07). Net daily ultrafiltration was similar for the two treatment modalities (EDD, median, 3,000 mL/d; ran ge, 1,763 to 4,445 mL/d; CVVH, 3,028 mL/d; range, 1,785 to 4,707 mL/d; P = 0.514). Anticoagulation requirements were significantly less for patients t reated with EDD (median dose of heparin, 4,000 U/d; range, 0 to 5,800 U/d v ersus 21,100 U/d; range, 8,825 to 31,275 U/d for patients treated with CVVH ; P < 0.001). We found that EDD eliminated the need for constant supervisio n of the dialysis machine by a subspecialty dialysis nurse, allowing one nu rse to manage more than one treatment. Overall, EDD was well tolerated by t he majority of patients, offered many of the same benefits provided by CVVH , and was technically easier to perform. (C) 2000 by the National Kidney Fo undation, inc.